Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels. The latest shareholding structure of Financière de Tubize SA is available here

Shareholder Structure

Source

Latest notifications and shareholder identification (as of October 2025), UCB underlying ownership analysis

close

62% Free Float

Institutional investors:
Geographic distribution

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

Shareholders' Meeting Archives

Title Format Download
Abolition of UCB bearer shares (ENG)
PDF
Abolition of UCB bearer shares (FR)
PDF
Abolition of UCB bearer shares (NL)
PDF


Consensus

Estimates based on Visible Alpha consensus1 dated 04.03.2026.

Estimates include 7 broker models2 collaborating with Visible Alpha.

UCB FY Consensus Earnings Estimates (Average)
In € million2025a 2026e2027e2028e2029e2030e
Net Sales7,3888,1169,20210,27011,22212,054
Revenue7,7418,4699,57610,59111,51412,325
Adjusted EBIT2,0092,1932,8053,4854,0874,608
Adjusted EBITDA2,6362,8383,4254,1264,7955,340
Adj. EBITDA ratio34.1%33.5%35.8%39.0%41.6%43.3%
Net Profit1,5581,7132,1952,7323,2863,746
Core EPS (€)9.9910.9713.7416.8220.1622.82
 
UCB FY Consensus Product Sales Estimates (Average)
In € million2025a 2026e 2027e 2028e2029e2030e
Product Portfolio      
Cimzia1,9541,7851,6271,3611,131965
Bimzelx2,2273,2214,3295,3676,2927,055
Evenity*137176207229243254
Rystiggo332459581683770841
Zilbrysq217344461573665728
Vimpat303238205188173160
Keppra439389364341316295
Briviact758416278223190163
Fintepla427518622692729756
Nayzilam12813313712811085
Potential New Products non-risk adjusted    
Dapirolizumab pegol   91176308
Staccato alprazolam  265689116
Bepranemab   73204317
Kygevvi 315986117154

*European sales, ex-EU sales booked by Amgen/Astellas

 

  • 1Disclaimer

    The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
    Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
    In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

  • 2Contributing brokers
    BrokerModel date
    AlphaValue

    3-Mar-2026

    BofA

    27-Mar-2026

    Cowen

    26-Feb-2026

    Deutsche Bank

    3-Mar-2026

    Redburn

    3-Mar-2026

    UBS

    27-Mar-2026

    Goldman Sachs

    2-Mar-2026

     


Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposes to pay a gross dividend of € 1.39 per share (gross), to be approved by the annual general meeting of the shareholders.

  • Coupon # 28
  • Ex-dividend: 25 April 2025
  • Record date: 28 April 2025
  • Payment: 29 April 2025

Coupon # 28 of UCB shares is payable at € 0.973 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.


Contact UCB IR Team

investor-relations@ucb.com or a specific team member:

Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com



Sahar Yazdian, Investor Relations Lead

Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com

UCB IR App

ucb ir app
App Store


 

Google Play